Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc. (FENC) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · FENC · as of Sep 30, 2025
Ownership Breakdown
84
Institutional Holders
▲ 6 vs Q2
$129.76M
Total Inst. Value
▲ $16.88M vs Q2
28.58M
Shares Outstanding
freeFloat 47.81%
13.86M
13F Shares Held
▲ 263,356 vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
FENC largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
SOUTHPOINT CAPITAL ADVISORS LP biological products, (no diagnostic substances) | 4.08M | 14.74% | 14.74% | $38.16B | Nov 14, 2025 | — held |
SOLAS CAPITAL MANAGEMENT, LLC biological products, (no diagnostic substances) | 2.19M | 7.91% | 7.91% | $20.48B | Nov 14, 2025 | ▼ 45.0K |
ROSALIND ADVISORS, INC. biological products, (no diagnostic substances) | 2.08M | 7.51% | 7.51% | $19.44B | Nov 13, 2025 | ▲ 31.2K |
BLACKROCK, INC. biological products, (no diagnostic substances) | 1.21M | 4.38% | 4.38% | $11.34B | Nov 12, 2025 | ▼ 14.6K |
VANGUARD GROUP INC biological products, (no diagnostic substances) | 955.8K | 3.45% | 3.45% | $8.95B | Nov 7, 2025 | ▼ 11.3K |
AIGH CAPITAL MANAGEMENT LLC biological products, (no diagnostic substances) | 681.5K | 2.46% | 2.46% | $6.38B | Oct 31, 2025 | ▲ 229.1K |
STATE STREET CORP biological products, (no diagnostic substances) | 341.2K | 1.23% | 1.23% | $3.19B | Nov 14, 2025 | ▲ 4.7K |
TANG CAPITAL MANAGEMENT LLC biological products, (no diagnostic substances) | 334.6K | 1.21% | 1.21% | $3.13B | Nov 14, 2025 | ▲ 314.1K |
GEODE CAPITAL MANAGEMENT, LLC biological products, (no diagnostic substances) | 300.8K | 1.09% | 1.09% | $2.82B | Nov 12, 2025 | ▼ 3.8K |
MORGAN STANLEY biological products, (no diagnostic substances) | 232.4K | 84.01% | 84.01% | $2.18B | May 27, 2026 | ▼ 21.8K |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
16
Increased
+695.6K shares5
New Positions
first time holders21
Decreased
−342.4K shares0
Sold Out
fully exitedNet shares change (top 50)
+353.2K
+695.6K / −342.4K
Net new holders
+0
5 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
FENC insider trading · insider activity
Source: SEC Form 4
Insiders have been primarily selling shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
16
Buy transactions
8
Sell transactions
2.00
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Raykov Rosty director | Jun 1, 2026 | Sale | 9,747 | $9.62 | $93.8K | 130.1K | Form 4 ↗ |
Raykov Rosty director | May 31, 2026 | Award | 2,778 | — | — | 124.2K | Form 4 ↗ |
Cioffi Christiana Marie Chief Strategy Officer | May 31, 2026 | Award | 156 | — | — | 24.2K | Form 4 ↗ |
Evans Terry L Chief Commercial Officer | May 31, 2026 | Award | 168 | — | — | 21.0K | Form 4 ↗ |
Sayad Pierre Sargis Chief Medical Officer | May 31, 2026 | Award | 168 | — | — | 21.0K | Form 4 ↗ |
Hackman Jeffrey S. Chief Executive Officer | May 31, 2026 | Award | 1,159 | — | — | 62.8K | Form 4 ↗ |
Andrade Robert CHIEF FINANCIAL OFFICER | May 31, 2026 | Award | 1,703 | — | — | 289.3K | Form 4 ↗ |
RALLIS CHRIS A director | May 11, 2026 | Sale | 8,346 | $7.04 | $58.8K | 63.1K | Form 4 ↗ |
Raykov Rosty director | May 1, 2026 | Sale | 10,781 | $6.47 | $69.8K | 121.5K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Fennec Pharmaceuticals Inc. (FENC) is primarily owned by institutional investors, who hold approximately 48.5% of total shares outstanding. Company insiders own approximately 52.19%, while retail and public investors account for the remaining 0.00%.
The largest institutional shareholder of Fennec Pharmaceuticals Inc. is SOUTHPOINT CAPITAL ADVISORS LP, holding approximately 4.08 million shares — equal to 14.74% of outstanding shares — as of September 30, 2025.
A total of 84 institutional investors currently hold FENC stock, with a combined institutional value of approximately $129,758,179 as of the most recent 13F filing period.
Frequently asked questions
FENC ownershipFennec Pharmaceuticals Inc. (FENC) is primarily owned by institutional investors, who hold approximately 48.5% of shares. The largest shareholder is SOUTHPOINT CAPITAL ADVISORS LP with a 14.74% stake. Company insiders hold 52.19%. Data sourced from SEC Form 13F as of September 30, 2025.